

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. - 4. (canceled)
5. (previously presented) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence SEQ ID NO: 4.
6. (previously presented) The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises the nucleotide sequence SEQ ID NO: 3.
7. (previously presented) The nucleic acid molecule of claim 5, wherein the nucleic acid molecule encodes a polypeptide consisting of the amino acid sequence SEQ ID NO: 4.
8. (previously presented) The nucleic acid molecule of claim 5, wherein the nucleic acid molecule consists of the nucleic acid sequence SEQ ID NO: 3.
9. (previously presented) The nucleic acid molecule of claim 5, wherein said nucleic acid molecule comprises the nucleic acid sequence SEQ ID NO: 3.
10. - 11. (canceled)
12. (previously presented) A vector comprising the nucleic acid molecule of claim 5.
13. (original) The vector of claim 12, further comprising a promoter operably-linked to said nucleic acid molecule.
14. (previously presented) An isolated cell comprising the vector of claim 12.

15. – 18. (canceled)

19. (withdrawn) A method for determining the presence or amount of the nucleic acid molecule of claim 5 in a sample, the method comprising:
- (a) providing the sample;
  - (b) contacting the sample with a probe that binds to said nucleic acid molecule; and
  - (c) determining the presence or amount of the probe bound to said nucleic acid molecule,
- thereby determining the presence or amount of the nucleic acid molecule in said sample.

20. (withdrawn) The method of claim 19 wherein presence or amount of the nucleic acid molecule is used as a marker for cell or tissue type.

21. (withdrawn) The method of claim 20 wherein the cell or tissue type is cancerous.

22. - 38. (canceled)

39. (previously presented) A composition comprising the nucleic acid molecule of claim 5 and a carrier.

40. - 41. (canceled)

42. (previously presented) A kit comprising in one or more containers, the composition of claim 39.

43. - 49. (canceled)

50. (withdrawn) A method for determining the presence of or predisposition to a disease associated with altered levels of the nucleic acid molecule of claim 5 in a first mammalian subject, the method comprising:
- (a) measuring the amount of the nucleic acid in a sample from the first mammalian subject; and

Applicants: Edinger, et al  
U.S.S.N.: 10/087684

- (b) comparing the amount of said nucleic acid in the sample of step (a) to the amount of the nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease;

wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.

- 51. (withdrawn) The method of claim 50, wherein the predisposition is to a cancer.